Abstract:The rational design of novel drug candidates presents a formidable challenge in modern drug discovery. Proteolysis-targeting chimeras (PROTACs) drug design is particularly demanding due to their limited crystal structure availability and design of a viable small molecule to bridge the protein of interest (POI) and ubiquitin-protein ligase (E3). An integrated approach that combines superimposition techniques and deep neural networks is demonstrated in this study to leverage the power of deep learning and structural biology to generate structurally diverse molecules with enhanced binding affinities. The superimposition technique ensures the congruence of initial and new protein-ligand pairs, which are evaluated via subsequent comprehensive screening using the root-mean-square deviation (RMSD), binding free energy (BFE), and buried solvent-accessible surface area (SASA). The final candidates are subjected to the incorporation of molecular dynamics (MD) and free energy perturbation (FEP) simulations to provide a quantitative evaluation of relative binding energies, reinforcing the efficacy and reliability of the generated molecules. The outcomes of the generated novel PROTACs molecules exhibit comparable structural attributes while demonstrating superior binding affinities within the binding pockets when contrasted with those of the established cocrystal ternary complexes. To enhance the generalizability of the workflow, we chose the ternary structure of the cellular inhibitor of apoptosis protein 1 (cIAP1) and Bruton's Tyrosine Kinase (BTK) for validating the chemical properties generated from the processes. The new linker molecules additionally showed superior affinity from the simulations. In summary, this methodology serves as an effective workflow to align computational predictions with current limitations, thereby introducing a novel paradigm in AI-driven drug design.

Rational Design of TNFα Binding Proteins Based on the De Novo Designed Protein DS119

De Novo Design TNF-α Antagonistic Peptide Based on the Complex Structure of TNF-α with Its Neutralizing Monoclonal Antibody Z12

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

Computational Design And Optimization Of Novel D-Peptide Tnf Alpha Inhibitors

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Novel human single chain antibody design based on the functional epitope of TNF

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

Design of High Affinity Binders to Convex Protein Target Sites

De Novo Design of Helical Peptides to Inhibit Tumor Necrosis Factor-Α by Disrupting Its Trimer Formation

De novo-designed transmembrane domains tune engineered receptor functions

Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists

Engineering a Zinc Binding Site into the De Novo Designed Protein DS119 with a Βαβ Structure.

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

De novo design of protein interactions with learned surface fingerprints

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

De novo design of drug-binding proteins with predictable binding energy and specificity

De novo-designed transmembrane proteins bind and regulate a cytokine receptor

Robust de novo design of protein binding proteins from target structural information alone

De novo design of protein minibinder agonists of TLR3